Medical technology company IDx, LLC recently announced a five-year strategic alliance with IBM Watson Health to advance eye health through cognitive computing applications, ultimately helping primary care providers, hospitals, health systems, and integrated delivery networks deliver value-based care to patients with diabetic retinopathy and other serious eye conditions such as glaucoma and age-related macular degeneration.
The alliance reportedly leverages more than 10 years of IDx's ophthalmic image analysis work and IBM's cognitive healthcare offerings and global reach, and will expand IBM Watson Health's focus on eye health. IDx also recently joined the global IBM Watson medical imaging collaborative, which includes 24 members worldwide.
Initially, IBM Watson Health intends to distribute IDx-DR — an automated solution for diabetic retinopathy screening currently available in the 31 countries that comprise the European Economic Area. IBM Watson Health may reportedly expand its distribution of IDx-DR to Australia, Canada, and the United States upon regulatory approvals of the product.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.